Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

Published:2014-06 Issue:6 Volume:2 Page:464-473
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Diamant Michaela,Van Gaal Luc,Guerci Bruno,Stranks Stephen,Han Jenny,Malloy Jaret,Boardman Marilyn K,Trautmann Michael E

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference33 articles.

1. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing;Fineman;Clin Pharmacokinet,2011

2. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study;Drucker;Lancet,2008

3. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial;Bergenstal;Lancet,2010

4. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial;Diamant;Lancet,2010

5. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study;Russell-Jones;Diabetes Care,2012

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Glucose and Lipid Metabolism and Visceral Fat in Overweight and Obese Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide Combined with Dapagliflozin;Advances in Clinical Medicine;2024

2. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis;Diabetes and Vascular Disease Research;2023-11

3. Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus;Primary Care Diabetes;2023-10

4. Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes;IJC Heart & Vasculature;2023-08

5. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials;Minerva Endocrinology;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3